Grifols is a global, Spanish-based biotech company that is a favorite for many European investors, despite the fact that the company does not pay a dividend. It's one of the more well-known Spanish ...
Seeking Alpha: Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale
It's time for an update on the Medical company Grifols, S.A. (GRFS). It's been about 4 months since I last updated on the business, with that update being specific to an event where Brookfield Asset ...
Grifols S.A. Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment ...
Grifols S.A. ADR Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on ...
Grifols, S.A. has executed a turnaround, with Q3 '25 results confirming improved fundamentals, reduced leverage, and restored dividend, supporting a renewed 'Buy' rating. GRFS now trades at a ...
Yahoo Finance UK: Assessing Grifols (BME:GRF) Valuation After Recent Share Price Weakness And Perceived Discount
Recent performance context for Grifols Grifols (BME:GRF) has drawn investor attention after a mixed run, with a modest 1 day gain, a negative move over the past week and month, and a deeper decline ...
Assessing Grifols (BME:GRF) Valuation After Recent Share Price Weakness And Perceived Discount
Seeking Alpha: Grifols: Upside After A Smashing Q1 2023 - I Say 'Buy'
My first take on Grifols, S.A. (GRFS) was poorly timed. The company declined immediately after my piece, and my initial stake went down a bit. I did, however, buy some more, and this balancing of ...